Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning

Inclusion Criteria:

* Patients must have histopathology confirmed prostate cancer that is Gleason score ≤7(4+3) clinical stage ≤ T2bN0M0 with a Prostate-specific antigen (PSA) below 15 ng/mL.
* Patients must have MRI findings reporting intraprostatic lesions suspicious for malignancy.
* Patient must not have had any prior treatment for prostate cancer
* Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
* Subjects must have an International Prostate Symptom Score of ≤ 15.
* Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Gleason score of ≥ 8(4+4)
* PSA ≥ 15 ng/mL.
* Clinical stage \>T2b or evidence of nodal
* Patients who are on anticoagulants or high dose aspirin therapy that cannot be safely stopped for greater than 10 days prior to treatment should be excluded to limit increased risk for urinary obstruction.
* Patients with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* HIV-positive patients on combination antiretroviral therapy are ineligible because of the unlikely risk of prostate cancer being life threatening in this population.